Pharmaceutical formulation comprising (r) -bicalutamide
CA 2462219 A1 · Owner: Bateman, Nicola Frances · Inventors: Bateman, Nicola Frances; Cahill, Julie Kay
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a pharmaceutical formulation comprising the drug 4'-cyano-.alpha.', .alpha.', .alpha.'-trifluoro-3-(4fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m-toluidide in a solid dispersion with an enteric polymer having a pKa from 3 to 6 wherein > 50 % of , the drug is provided in the form of the R-enantiomer. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of an enteric polymer having a pKa from 3 to 6 in solid dispersion with the drug wherein > , 50 % of the drug is provided in the form of the R-enantiomer for increasing , the bioavailability of the drug; …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 11, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 11, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 11, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.